Navigation Links
Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes

doses of sitagliptin. Clinically meaningful interactions would not be expected with other sulfonylureas (e.g., glipizide, tolbutamide, and glimepiride) which, like glyburide, are primarily eliminated by CYP2C9. However, the risk of hypoglycemia from the co-administration of sitagliptin and sulfonylureas is unknown. Simvastatin: Single-dose pharmacokinetics of simvastatin, a CYP3A4 substrate, was not meaningfully altered in subjects receiving multiple daily doses of sitagliptin. Therefore, sitagliptin is not an inhibitor of CYP3A4-mediated metabolism. Thiazolidinediones: Single-dose pharmacokinetics of rosiglitazone was not meaningfully altered in subjects receiving multiple daily doses of sitagliptin, indicating that JANUVIA is not an inhibitor of CYP2C8-mediated metabolism. Warfarin: Multiple daily doses of sitagliptin did not meaningfully alter the pharmacokinetics, as assessed by measurement of S(-) or R(+) warfarin enantiomers, or pharmacodynamics (as assessed by measurement of prothrombin INR) of a single dose of warfarin. Because S(-) warfarin is primarily metabolized by CYP2C9, these data also support the conclusion that sitagliptin is not a CYP2C9 inhibitor. Oral Contraceptives: Co-administration with sitagliptin did not meaningfully alter the steady-state pharmacokinetics of norethindrone or ethinyl estradiol. Effects of Other Drugs on Sitagliptin Clinical data described below suggest that sitagliptin is not susceptible to clinically meaningful interactions by co-administered medications: Metformin: Co-administration of multiple twice-daily doses of metformin with sitagliptin did not meaningfully alter the pharmacokinetics of sitagliptin in patients with type 2 diabetes. Cyclosporine: A study was conducted to assess the effect of cyclosporine, a potent inhibitor of p-glycoprotein, on the pharmacokinetics of sitagliptin. Co-administration of a single 100 mg oral dose of JANUVIA and a sin
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
2. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
5. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
6. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
7. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
8. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
9. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
10. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
(Date:8/20/2014)... LONDON , Aug. 20, 2014 Reportbuyer.com ... Global Cardiac Defibrillators Industry https://www.reportbuyer.com/product/98394/Global-Cardiac-Defibrillators-Industry.html ... Cardiac Defibrillators in US$ Million by the following Product ... provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ...
(Date:8/20/2014)... 20, 2014 Research and Markets  has announced ... report to their offering. Global Market ... on Pralmorelin globally and regionally ( Europe , ... , Latin America etc.). It captures ... This report focuses on three primary areas; manufacture methods & ...
(Date:8/20/2014)... Aug. 20, 2014  Decision Resources Group ... and ablation device market will expand through ... treat atrial fibrillation (AF). The increasing acceptance ... for AF will spur adoption of premium-priced ... as advanced loop diagnostic catheters, cryoablation catheters ...
Breaking Medicine Technology:Global Cardiac Defibrillators Industry 2Global Cardiac Defibrillators Industry 3Global Cardiac Defibrillators Industry 4Global Cardiac Defibrillators Industry 5Global Cardiac Defibrillators Industry 6Global Cardiac Defibrillators Industry 7Global Cardiac Defibrillators Industry 8Global Cardiac Defibrillators Industry 9Global Cardiac Defibrillators Industry 10Global Cardiac Defibrillators Industry 11Global Cardiac Defibrillators Industry 12Global Cardiac Defibrillators Industry 13Global Cardiac Defibrillators Industry 14Global Cardiac Defibrillators Industry 15Global Cardiac Defibrillators Industry 16Global Cardiac Defibrillators Industry 17Global Cardiac Defibrillators Industry 18Global Cardiac Defibrillators Industry 19Global Cardiac Defibrillators Industry 20Global Market Report of Pralmorelin 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3
... WASHINGTON, Oct. 31 The following is being,issued by ... will hold a news conference about the lawsuit it ... Agriculture (USDA),to prevent the agency from allowing into the ... cattle over 30 months (OTM) of age,scheduled to begin ...
... Vice President of Scientific Affairs Dr. Randy Huffman ... Fund report, slated for,release October 31. Dr. Huffman ... WCRF,s 9:30 a.m. press conference., The American ... largest,association representing U.S. meat and poultry packers and ...
Cached Medicine Technology:R-CALF United Stockgrowers of America: 'Fighting for the U.S. Cattle Producer' 2
(Date:8/20/2014)... Park Cities Pet Sitter , Inc. has announced ... donation drive that benefits the animal shelter and rescue communities. ... with the Humane Society of the United States’ Animal Shelter ... , As part of their participation, Park Cities Pet Sitter ... the Presents 4 Pets drive from their client base, as ...
(Date:8/20/2014)... Aug. 20, 2014 A common approach to treating ... did not improve survival chances for people who suddenly ... at the University of Pittsburgh School of Medicine. , ... One , suggest acute hemodialysis, an aggressive method that ... may not provide a definitive benefit to the patient. ...
(Date:8/20/2014)... August 20, 2014 With 3943.8% growth, Connexion ... of the nation’s fastest growing companies. The Inc. 500 ranks ... care sector. Connexion Point is the #1 fastest growing company ... Medicare and Medicaid, and its clients include four of the ... employs 1,000 people and has offices and contact centers in ...
(Date:8/20/2014)... novel approach to treating cancer - using Botox. A ... Science Translational Medicine shows that cancer growth could ... that are linked to cancer stem cells. The approach ... the treatment cheap, safe and efficient. The researchers have ... soon start testing on humans. , The nervous system ...
(Date:8/20/2014)... YORK -- The most common cause of endophthalmitis, a ... eye surgery, and eye injections, are the well-known ... strains, according to a study published in the August ... review of 25 years of cases at New York ... , The new study found that gram-positive bacteria, which ...
Breaking Medicine News(10 mins):Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 2Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 3Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 4Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:With 3943.8% Growth, Connexion Point, a Leader in Contact Centers for Health Care, Ranks 86th on the Inc. 500 List as One of the Nation’s Fastest Growing Companies 2Health News:Treating gastric cancer -- with Botox 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 3
... Delcath Systems, Inc. (Nasdaq: DCTH ... proprietary Percutaneous Hepatic Perfusion ("PHP(TM)") System for the treatment ... James F. Pingpank will present at The Sixth International ... City on March 13-14, 2009. (Logo: ...
... CDC says more emphasis needed on tobacco-control programs , , ... marketing and promotion and tobacco-control programs are among the ... in some states than others, according to a new ... Prevention. , About 28 percent of adults in Kentucky ...
... Safe to Eat and Who,s Most At RiskLANSING, Ill., ... safety legislation under debate in the U.S. Senate and ... Americans are more concerned than ever when it comes ... unaware of the long-term side effects of Salmonella, one ...
... Choosing to have aggressive brain surgery after suffering a ... them to live longer, according to research by neurologists ... findings should help patients and families put into perspective ... to make whether putting a patient through aggressive ...
... citizens and the European medical industry and facilitate the ... the bedside. For Europe and for the rest of ... for the quality of life of individuals and the ... achieve this important objective, the European Medical Research Councils ...
... condition will affect more than 78 million U.S. ... lenses can resolve their vision needs to avoid ... manufacturer of the #1 multifocal lens design, has ... goal of raising U.S. awareness of presbyopia and ...
Cached Medicine News:Health News:Dr. James F. Pingpank to Present at the Sixth International Symposium on Melanoma and Other Cutaneous Malignancies on March 13- 14, 2009 in New York City 2Health News:Dr. James F. Pingpank to Present at the Sixth International Symposium on Melanoma and Other Cutaneous Malignancies on March 13- 14, 2009 in New York City 3Health News:Smoking Isn't Falling as Fast as Officials Hoped: Report 2Health News:Food Safety Expert: Americans Not Aware of Ongoing Risk & Complications of Salmonella Poisoning 2Health News:Food Safety Expert: Americans Not Aware of Ongoing Risk & Complications of Salmonella Poisoning 3Health News:Weighing the options after life-altering stroke 2Health News:Weighing the options after life-altering stroke 3Health News:Weighing the options after life-altering stroke 4Health News:Better health and prosperity in Europe via improved clinical research 2Health News:Bausch & Lomb Launches Multi-Tiered U.S. Consumer Education Initiative to Raise Awareness of Presbyopia 2Health News:Bausch & Lomb Launches Multi-Tiered U.S. Consumer Education Initiative to Raise Awareness of Presbyopia 3
... you need spirometry tests,performed ... at a patients,home, the ... the healthcare practitioner on ... allows easy,navigation, while Sensaires ...
ASAP™ Automated Biopsy System with Channel Cut™ Needle....
Incontinence Pessaries...
Incontinence Dish - Stress Incontinence with mild prolapse. Incontinence Dish with support - Stress Incontinence with mild prolapse and mild cystocele...
Medicine Products: